Immunization against the varicella-zoster virus (VZV) is an important strategy for preventing VZV infection in susceptible health care workers.1 However, the VZV vaccine is a live attenuated virus that has the potential to replicate and cause disease in vivo, particularly in immunocompromised hosts.2-4 Whenever live attenuated vaccines are administered, care should be taken to ensure that recipients are not immunocompromised. We describe a heart transplant recipient who developed cutaneous Oka strain vaccine lesions requiring hospitalization after routine hospital preemployment immunization status screening.
Kraft JN, Shaw JC. Varicella Infection Caused by Oka Strain Vaccine in a Heart Transplant Recipient. Arch Dermatol. 2006;142(7):927–947. doi:10.1001/archderm.142.7.943
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: